Market Research Logo

Anticoagulants Market in the US 2016-2020

About the Anti-Coagulant Drugs Market

Anticoagulants have been used for over 80 years to treat clotting disorders. It is used as a first line of defense for disorders such as deep vein thrombosis (DVT), pulmonary embolism, AF, and acute coronary syndrome. With the advent of time, traditional therapies are replaced by novel oral anticoagulants, which have better safety and efficacy profiles.The 1990s saw rapid development in the field of direct thrombin inhibitors. Though these drugs, such as hirudin, have been in use from the early 19th century, they were accepted with the development of genetic engineering technology. The recombinant forms, such as desirudin, are also available in the market. During the same period, the focus shifted toward the development of factor Xa inhibitors, and by early 2000s, the first indirect factor Xa inhibitor, fondaparinux, was released into the market. These drugs were administered by parenteral route.

Technavio’s analysts forecast the anti-coagulants market in the US to grow at a CAGR of 6.67% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the anti-coagulants market in the US for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded and generics drugs used to treat coagulation disorders. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market.Technavio's report, Anti-Coagulants Market in the US 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Johnson & Johnson
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
  • Sanofi
  • Daiichi Sankyo
Other prominent vendors
  • Armatheon Inc.
  • Aspen
  • AstraZeneca
  • Bayer
  • Cellceutix
  • Cosmo Pharmaceuticals SA
  • CSL Behring, Eisai, GSK
  • Marathon Pharmaceuticals LLC
  • Ockham Biotech
  • Perosphere
  • Portola Pharmaceuticals
  • Sagent Pharmaceuticals Inc.
  • The Medicines Company
  • Urigen Pharmaceuticals Inc.
  • Valeant Pharmaceuticals
Market driver
  • Growing prevalence of coagulation disorders
  • For a full, detailed list, view our report
Market challenge
  • Side-effects associated with drugs
  • For a full, detailed list, view our report
Market trend
  • Expected exploitation of new therapeutic use
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Anti-Coagulants Market in the US 2016-2020

Technavio recognizes the following companies as the key players in the Anti-Coagulants Market in the US: Johnson & Johnson, Bristol-Myers Squibb, Boehringer Ingelheim, Sanofi, and Daiichi Sankyo.

Other Prominent Vendors in the market are: Armatheon Inc., Aspen, AstraZeneca, Bayer, Cellceutix, Cosmo Pharmaceuticals SA, CSL Behring, Eisai, GSK, Marathon Pharmaceuticals LLC, Ockham Biotech, Perosphere, Portola Pharmaceuticals, Sagent Pharmaceuticals Inc., The Medicines Company, Urigen Pharmaceuticals Inc., and Valeant Pharmaceuticals.

Commenting on the report, an analyst from Technavio’s team said: “A trend to look forward to would be new therapeutic uses for anti-coagulant drugs. Using anticoagulants for purposes other than the normal anticoagulation effects will widen the scope of the market and help in gaining higher revenues. Heparin and related drugs are widely used for their anticoagulant activities. However, it has been identified that heparin exhibits anti-inflammatory activities and prevents the metastatic spread of tumor cells. Heparin exhibits anti-inflammatory activity by neutralizing cationic mediators, inhibiting adhesion molecules, and inhibiting heparanase, all of which are involved in leukocyte recruitment into tissues. Similarly, research studies indicate that heparins acts as an inhibitor of cell adhesion and thereby elicit anti-metastatic activities.”

According to the report, a key growth driver would be the growing prevalence of coagulation disorders. Anticoagulants are prescribed in conditions such as AF, DVT, pulmonary embolism, stroke, clotting disorders, heart attack, and renal diseases. Cardiovascular disorders, kidney disorders, and strokes are becoming more prevalent due to unhealthy lifestyles among individuals, including a lack of physical activity, excessive alcohol consumption, and smoking. It is estimated that 900,000 people are affected each year by DVT or pulmonary embolism, and 60,000-100,000 individuals die of this condition in the US. They are a major cause of maternal and hospital deaths in the US. Heart diseases are the leading cause of death in the region, with an estimated 610,000 deaths reported every year.

Further, the report states that one challenge that could hamper market growth is the side effects associated with drugs.

Companies Mentioned

Johnson & Johnson, Bristol-Myers Squibb, Boehringer Ingelheim, Sanofi, Daiichi Sankyo, Armatheon Inc., Aspen, AstraZeneca, Bayer, Cellceutix, Cosmo Pharmaceuticals SA, CSL Behring, Eisai, GSK, Marathon Pharmaceuticals LLC, Ockham Biotech, Perosphere, Portola Pharmaceuticals, Sagent Pharmaceuticals Inc., The Medicines Company, Urigen Pharmaceuticals Inc., Valeant Pharmaceuticals.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
      • Table Timeline for development of anticoagulants
  • Anticoagulants: An overview
    • Coagulation of blood
      • Table Process of blood coagulation
      • Table Mechanism of blood coagulation
    • Mechanism of action (MOA) of anticoagulants
  • Reimbursement scenario
    • US healthcare reform
      • Table Comparison of US healthcare system before and after reforms
    • Reimbursement for prothrombin time/international normalized ratio (PT/INR) tests
  • Anticoagulant reversal agents
    • Table Major anticoagulant reversal agents commonly used in market
    • Table Reversal agents approved by FDA for new oral anticoagulants
    • Table Pipeline portfolio: Anticoagulant reversal agents
  • Approved anticoagulants in US
    • Table Approved anticoagulants in US
  • Anticoagulants pipeline portfolio
    • Table Pipeline portfolio: Anticoagulant drugs
    • Rivaroxaban
    • Tecarfarin
    • Betrixaban (LY517717)
    • ISIS-FXI antisense
    • LMW Heparin MMX
    • URG101
    • Heparin
    • FXI antibody
    • FXI inhibitor
    • Heparin plus DNAse
    • Heparin plus other inhaled drug
  • Market landscape
    • Global anticoagulants market
      • Table Global anticoagulants market 2015-2020 ($ billions)
    • Anticoagulants market in US
      • Table Percentage share of US anticoagulants market in global market
      • Table Anticoagulants market in US 2015-2020 ($ billions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by ROA
    • Table Segmentation of anticoagulants market in US based on ROA
    • Table Market segmentation of anticoagulants market in US based on ROA 2015
    • Table Comparison of US anticoagulants market with global anticoagulants market 2015
    • Oral anticoagulants
      • Table Percentage of population treated by NOACs based on disease type in US 2015
      • Table Factors determining use of NOACs (based on their importance)
      • Table Percentage of individuals with AF treated by anticoagulants in US 2015
      • Table Percentage of individuals with DVT/PE treated by anticoagulants in US 2015
      • Table Classes of oral anticoagulants based on revenue 2015
      • Table Oral anticoagulants market in US 2015-2020 ($ billions)
    • Injectable anticoagulants
      • Table Classes of injectable anticoagulants based on revenue 2015
      • Table Injectable anticoagulants market in the US 2015-2020 ($ billions)
      • Table Anticoagulants market in US by ROA 2015-2020
      • Table Anticoagulants market in US: YoY growth and revenue based on ROA 2015-2020
  • Market segmentation by drug class
    • Table Segmentation of anticoagulants market in US based on drug class
    • Table Segmentation of anticoagulants market in US based on drug class 2015
    • Table Anticoagulants market in US in global anticoagulant drugs market 2015
    • Factor Xa inhibitors
      • Table Segmentation of factor Xa inhibitors in US 2015
      • Table Approval of factor Xa inhibitor drugs in US
      • Table Factor Xa inhibitor drugs market in US 2015-2020 ($ billions)
    • Direct thrombin inhibitors
      • Table Some direct thrombin inhibitor drugs approved in US
      • Table Direct thrombin inhibitors market segmentation by ROA 2015
      • Table Direct thrombin inhibitor drugs market in US 2015-2020 ($ billions)
    • Heparin
      • Table Segmentation of global heparin market by product type 2015
      • Table Global heparin market 2015-2020 ($ billions)
      • Table Heparin market in US 2015-2020 ($ billions)
    • Vitamin K antagonists
      • Table Vitamin K antagonists market in US 2015-2020 ($ millions)
      • Table Anticoagulants market in US by drug class 2015-2020
      • Table Anticoagulants market in US: YoY growth and revenue based on drug class 2015-2020
  • Market segmentation by application
    • DVT
    • PE
    • Acute coronary syndrome
    • AF
    • Hemodialysis
    • Coronary angioplasty
    • Surgeries
  • Market drivers
    • Growing prevalence of coagulation disorders
      • Table Expected growth of older population in US 2010-2050
    • Increase in number of surgical procedures
    • Increased acceptance of NOACs
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Extensive use of generic products
    • Side-effects associated with drugs
    • High cost of NOACs
    • Unmet needs for anticoagulant reversal agents
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Expected exploitation of new therapeutic use
    • Patient assistance programs
    • Declining shares of heparin market
  • Vendor landscape
    • Competitive scenario
    • Market analysis 2015
      • Table Share of the major anticoagulant drugs in US 2013-2015 ($ billions)
    • Key vendors of anticoagulants market in US
      • Johnson & Johnson
        • Table Johnson & Johnson: YoY revenue and growth rate of Xarelto in US 2013-2015 ($millions)
        • Table Johnson & Johnson: Key takeaways
    • Bristol-Myers Squibb
      • Table BMS: YoY revenue and growth rate of Eliquis in US 2013-2015 ($ millions)
      • Table BMS: Key takeaways
    • Boehringer Ingelheim
      • Table Boehringer Ingelheim: YoY revenue and growth rate of Pradaxa (global) 2013-2015($ billions)
      • Table Boehringer Ingelheim: Key takeaways
    • Sanofi
      • Table Sanofi: YoY revenue and growth rate of Lovenox in US 2013-2015 ($ millions)
      • Table Geographical segmentation of Lovenox 2015
      • Table Sanofi: Key takeaways
    • Upcoming vendors in anticoagulants market in US
      • Daiichi Sankyo
        • Table Key takeaways
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report